Skip to main content

Table 4 Outcomes of anakinra vs. no anakinra groups before and after propensity score matching

From: Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study

 

Before propensity score matching

After propensity score matching

Outcomes

Anakinra

(N = 57)

No Anakinra

(N = 52)

p value

Anakinra

(N = 31)

No Anakinra

(N = 31)

p-value

Duration of organ support, median (IQR)

  

Vasoactive support (hours)

19.6 (8.9–55.7)

20.6 (12.5–31.3)

0.25

16.2 (8.3–48.5)

19.1 (11.7–34.2)

0.64

Respiratory support (days)

3.0 (2.0-5.5)

2.0 (1.0-6.8)

0.23

5 (1–8)

2 (1–6)

0.14

Organ support, n (%)

  

Respiratory support

39 (68)

34 (65)

0.73

18 (58)

24 (77)

0.1

Vasoactive support

44 (77)

24 (46)

0.0008

21 (68)

22 (71)

0.78

VIS, day 1, median (IQR)

10.0 (6.0–15.0)

7.0 (5.0-10.2)

0.3

7.0 (6.0–13.0)

6.0 (5.0-9.5)

0.76

Presence of fever

  

Fever duration during admission (days), median (IQR)

1 (1–2)

2 (1–3)

0.09

2 (1–3)

1 (1–3)

0.43

Max temperature (oC), day 2, median (IQR)

37.3 (36.7–38.3)

38.2 (36.9–39.1)

0.01

37.9 (37.2–39.1)

38.2 (36.9–38.9)

0.84

Fever, day 2, n (%)

19 (33)

27 (52)

0.04

15 (48)

18 (58)

0.44

Max temperature (oC), day 3, median (IQR)

37.1 (36.8–37.9)

37.2 (36.8–38.1)

0.23

37.3 (36.7–38.7)

37.2 (36.7–37.8)

0.5

Fever, day 3, n (%)

12 (21)

12 (23)

0.79

10 (32)

6 (19)

0.24

Fever, day 4, n (%)

6 (11)

13 (25)

0.046

5 (16)

8 (26)

0.34

Fever, day 5, n (%)

3 (5)

10 (19)

0.024

5 (16)

4 (13)

0.71

CRP, median (IQR)

  

CRP, day 2

16.5 (13.9–21.0)

15.2 (10.9–19.9)

0.21

15.7 (13.3–19.9)

16.4 (11.8–20.3)

0.72

CRP, day 3

11.6 (7.8–17.0)

10.9 (7.9–16.8)

0.25

11.6 (8.7–18.6)

11.3 (8.4–16.9)

0.62

VIS, median (IQR)

  

VIS, day 2

5.0 (4.3-8.0)

8.5 (4.0–16.0)

0.33

7.0 (6.0–13.0)

6.0 (5.0-9.5)

0.76

VIS, day 3

4.5 (2.0–7.0)

8.0 (5.8–10.0)

0.33

5.0 (4.0–8.0)

5.0 (2.0–11.0)

0.82

Echo findings

  

LV dysfunction, n (%)

24 (42)

8 (15)

0.94

9 (29)

9 (29)

1

LVSF, median (IQR)

30 (24–33)

32 (29–35)

0.01

32 (28–35)

32 (26–34)

0.28

CAA, n (%)

5 (9)

2 (4)

0.29

5 (16)

0 (0)

0.05

Length of stay (days), median (IQR)

  

ICU LOS

2.5 (1.3–4.3)

2.0 (1.6–5.9)

0.54

1.8 (1.1–5.5)

2.11 (1.7–6.2)

0.18

Hospital LOS

7.8 (6.7–10.2)

5.9 (4.4–8.4)

0.00007

8.7 (6.6–11.0)

6.1 (4.4–9.6)

0.002

Time from initial steroid dose to discharge

6.8 (6.0-9.6)

5.0 (4.0-6.8)

0.00001

8.1 (6.1–9.9)

5.2 (4.25–7.5)

0.0008